Join the Non-Small Cell Lung Cancer group to help and get support from people like you.
Non-Small Cell Lung Cancer News
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
Early, Virtual Palliative Care Feasible for Advanced Lung Cancer
TUESDAY, Sept. 17, 2024 – The delivery of early, virtual palliative care has similar effects on quality of life as in-person care in patients with advanced non-small cell lung cancer (NSCLC),...
Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC
FRIDAY, Sept. 13, 2024 – Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with previously treated advanced nonsquamous non-small...
Perioperative Nivolumab Beneficial for Resectable NSCLC
THURSDAY, Sept. 12, 2024 – For patients with resectable non-small-cell lung cancer (NSCLC), perioperative nivolumab is associated with event-free survival (EFS) benefit compared with neoadjuvant...
Alternative Explanation Conditions Often Delay Lung Cancer Diagnosis
WEDNESDAY, Sept. 11, 2024 – Conditions offering alternative explanations for lung cancer symptoms are associated with increased diagnostic intervals, according to a study published online Aug. 23 in...
Lung Complications + Rheumatoid Arthritis Increase Risk for Lung Cancer
FRIDAY, Sept. 6, 2024 – The risk for lung cancer is high in patients with rheumatoid arthritis (RA) and pulmonary complications, according to a study published online Sept. 3 in Modern Rheumatology. ...
Radiotherapy Dose to Cardiac Substructures Linked to Arrhythmias
TUESDAY, Aug. 27, 2024 – For patients with locally advanced non-small cell lung cancer, radiotherapy dose to discrete cardiac substructures is associated with pathophysiologically distinct...
Alternative Criteria Can ID High-Benefit Groups for Lung Cancer Screening
MONDAY, Aug. 19, 2024 – Simple alternative criteria for lung cancer screening (LCS) can identify high-benefit groups, especially among certain racial and ethnic-minority groups, according to a study...
Imfinzi Approved in the US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery
16 August 2024 – AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small c...
Many Nonsmokers Have Lung Nodules Linked to Cancer Risk
TUESDAY, Aug. 13, 2024 – Many nonsmokers have lung nodules that have been linked to lung cancer, a new study warns. About 42% of nonsmokers or former smokers have at least one lung nodule, which is...
Rheumatoid Arthritis Tied to Higher Risk for Lung Cancer
FRIDAY, Aug. 9, 2024 – Rheumatoid arthritis (RA) is associated with a significantly increased risk for lung cancer, according to a study published online July 28 in Arthritis & Rheumatology. Rebecca ...
Smoking & Vaping Together Raise Lung Cancer Risks Even Higher
FRIDAY, Aug. 2, 2024 – Experts have long suspected it, but a new study confirms that folks who vape and smoke tobacco face higher risks for lung cancer than if they'd done either alone. “From a p...
E-Cigarette Use Linked to Lower Use of Lung Cancer Screening
TUESDAY, July 9, 2024 – Electronic cigarette use is associated with a lower use of lung cancer screening (LCS), according to a research letter published online July 2 in JAMA Network Open. Qian...
Intensity-Modulated Radiotherapy Recommended for Locally Advanced Lung Cancer
TUESDAY, July 9, 2024 – Intensity-modulated radiotherapy (IMRT) is recommended for locally advanced non-small cell lung cancer (NSCLC) and appears to have good long-term outcomes, according to a...
Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
MONDAY, July 1, 2024 – For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as...
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low
FRIDAY, June 21, 2024 – The overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study...